For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

We use cookies to make our site as useful as possible.

Our Cookie Policy explains how you can opt-out of the cookies we use.

If you continue without changing your cookie settings, we'll assume you’re happy with this.

Continue Continue

United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Diagnostic & Therapeutic Solutions
    Custom solutions & partnerships

    Custom antibody development and commercial partnerships to advance your diagnostic and therapeutic discovery.

    Create custom solutions with us

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Supporting our customers and employees during the COVID-19 pandemic. Read more

miRNA cancer cells

MicroRNAs as biomarkers in cancer

Related

  • Benefits of our assays
    • What do I need?
      • Panels for your research
        • Learn more about miRNAs
          • Rise of miRNA research
            • miRNAs in exosomes
              • Review of methods
                  • Focus on biomarkers
                    • Cancer
                      • Immunology
                        • Nervous system
                          • Stem cells

                          Cancer research is leading the way in identifying microRNA (miRNA) signatures to diagnose and monitor disease. Find out about recent research into lung, prostate and breast cancer.

                          Recently, microRNAs (miRNAs) have emerged as a new type of cancer-specific biomarker. miRNAs are small (~22bp) highly conserved non-coding RNAs endogenously expressed in every cell type. They function as key regulators of gene expression by silencing target transcripts through base-pair complementation.

                          miRNAs can be secreted from cells and are found in a variety of body fluids including blood, saliva and urine, where they are quantifiable and extremely stable. For these reasons miRNAs are becoming ideal candidates as non-invasive biomarkers for potentially any human disease, including cancer (Schwarzenbach et al., 2014).

                          Driven by the importance of early cancer diagnosis and the need to distinguish between numerous cancer types, oncologists are leading the way in identifying and validating miRNA signatures to diagnose and monitor disease. Here we highlight recent promising results for lung cancer, breast cancer and prostate cancer.


                          miRNA biomarkers for early diagnosis of lung cancer

                          Lung cancer is notoriously difficult to detect in its early stages, therefore there is a real need for biomarkers for its diagnosis. A recent study performed genome-wide miRNA expression profiling in plasma samples of patients with non-small cell lung cancer (NSCLC), a form of the disease that accounts for up to 85% of all lung cancer cases (Wozniak et al., 2015).

                          The researchers identified a signature of 24 circulating miRNAs in plasma of early stage NSCLC patients that displayed high diagnostic value. This was one of the largest exploratory studies, profiling 754 miRNAs in 100 NSCLC patients, thus providing a strong and highly predictive miRNA signature obtained through rigorous statistical approaches.

                          Recent research has taken an extra step towards the clinic by taking potential miRNA biomarkers and trialing them in large-scale validation studies. Montani et al. (2015), used participants from the Continuous Observation of Smoking Subjects lung cancer screening program to test a 13-miRNA signature.

                          They found that monitoring this combination of miRNAs could detect the disease with an overall accuracy of 74.9%. These promising results mean that early detection of lung cancer is now that little bit closer.


                          miRNA biomarkers to predict prostate cancer

                          Prostate cancer accounts for almost 15% of all new cancers in men. Is it possible, therefore, to use circulating miRNAs to predict the risk of treatment failure for prostate cancer? This is what Singh et al. (2015) set out to investigate by profiling serum miRNA expression in prostate cancer patients that underwent radical prostatectomy.

                          The study initially identified a panel of 43 miRNAs that could distinguish between disease stages in 14 prostate cell lines and patient samples. From these, 34 miRNAs were also detectable in the serum of prostate cancer patients. Following validation studies, the researchers concluded that miR-222 and miR-125b were predictors of progression risk in these patients, which could also be used to augment treatment decisions.


                          A potential miRNA to identify triple negative breast cancer

                          Triple negative breast cancer (TNBC) is very difficult to treat and accounts for around 20% of all breast cancers in women, so there is an urgent need for biomarkers for early detection of this disease. A recent study used a microarray platform to look at the role of plasma miRNAs in TNBC (Shin et al., 2015).

                          The researchers identified a five miRNA signature (miR-92a-3p, miR-342-3p, miR-16, miR-21 and miR-199a-5p) that could discriminate TNBC from non-TNBC. Overall, miR-199a-5p showed the highest specificity and sensitivity in distinguishing stage and tumor subtypes, raising hopes that this miRNA might be able to be used for TNBC diagnosis in the future.

                          Circulating miRNAs have great potential for the diagnosis of cancers where there is an unmet need to be able to diagnose cancers at an early stage or distinguish between cancer types. Their presence in circulating biofluids provides non-invasive ways of establishing early prognosis, predicting treatment response and ascertaining progression risk.

                          Profile with confidence using our pre-designed panels

                          We have developed a miRNA cancer focus panels containing probes for 68 miRNAs selected from peer-reviewed studies. The miRNAs are differentially regulated in breast cancer, prostate cancer or lung cancer.

                          Skip the literature search and go straight to the bench. Profile with high sensitivity pre-selected miRNAs that are relevant to your research direct from crude biofluids or purified RNA.

                          • Learn more about the miRNA oncology focus panel >


                          References

                          • Montani F, Marzi MT, Dezi F, Dama E, Carletti RM, Bonizzi G, Bertolotti R, Bellomi M, Rampinelli C, Maisonneuve P, Spaggiari L, Veronesi G, Nicassio F, Di Fiore PP, Bianchi F (2015). miR-Test: A blood test for lung cancer early detection. J Natl Cancer Inst 107, djv063.
                          • Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer (2014). Nat Rev Clin Oncol 11, 145–156.
                          • Shin VY, Siu JM, Cheuk I, Ng EK, Kwong A (2015). Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer 112,1751–1759.
                          • Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ (2014). Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget 5, 824–840.
                          • Wozniak MB, Scelo G, Muller DC, Mukeria A, Zaridze D, Brennan P (2015). Circulating microRNAs as non-invasive biomarkers for early detection of non-small cell lung cancer. PLoS One 10, e0125026.



                          Get resources and offers direct to your inbox Sign up
                          A-Z by research area
                          • Cancer
                          • Cardiovascular
                          • Cell biology
                          • Developmental biology
                          • Epigenetics & Nuclear signaling
                          • Immunology
                          • Metabolism
                          • Microbiology
                          • Neuroscience
                          • Signal transduction
                          • Stem cells
                          A-Z by product type
                          • Primary antibodies
                          • Secondary antibodies
                          • Biochemicals
                          • Isotype controls
                          • Flow cytometry multi-color selector
                          • Kits
                          • Loading controls
                          • Lysates
                          • Peptides
                          • Proteins
                          • Slides
                          • Tags and cell markers
                          • Tools & Reagents
                          Help & support
                          • Support
                          • Make an Inquiry
                          • Protocols & troubleshooting
                          • Placing an order
                          • RabMAb products
                          • Biochemical product FAQs
                          • Training
                          • Browse by Target
                          Company
                          • Corporate site
                          • Investor relations
                          • Company news
                          • Careers
                          • About us
                          • Blog
                          Events
                          • Tradeshows
                          • Conferences
                          International websites
                          • abcam.cn
                          • abcam.co.jp

                          Join with us

                          • LinkedIn
                          • facebook
                          • Twitter
                          • YouTube
                          • Terms of sale
                          • Website terms of use
                          • Cookie policy
                          • Privacy policy
                          • Legal
                          • Modern slavery statement
                          © 1998-2021 Abcam plc. All rights reserved.